Literature DB >> 16762510

Biliary tract cancers: molecular profiling as a tool for treatment decisions. A literature review.

Rossana Berardi1, Berardi Rossana, Mario Scartozzi, Scartozzi Mario, Federica Freddari, Freddari Federica, Michela Squadroni, Squadroni Michela, Alfredo Santinelli, Santinelli Alfredo, Italo Bearzi, Bearzi Italo, Guidalberto Fabris, Fabris Guidalberto, Stefano Cascinu, Cascinu Stefano.   

Abstract

Biliary tract cancer is a quite rare disease; despite recent significant advances in imaging modalities, most of the patients have advanced disease at presentation thus making radical surgery not feasible. Many different chemotherapeutic regimens have been investigated in small uncontrolled studies, with generally disappointing results. We extensively reviewed the literature on this topic trying to give an explanation to chemoresistance in this setting of patients and considering the molecular profiling as a tool for treatment decision. This review is divided in two parts, in the first one we illustrated chemotherapy results and possible mechanisms of resistance. In the second part we analysed the new molecular targets developing an hypothesis about the future therapeutics perspectives.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762510     DOI: 10.1016/j.ctrv.2006.03.003

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  3 in total

1.  Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.

Authors:  Mary Potkonjak; John T Miura; Kiran K Turaga; Fabian M Johnston; Susan Tsai; Kathleen K Christians; T Clark Gamblin
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

2.  Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.

Authors:  Li-Ning Xu; Xin Wang; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

3.  Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.

Authors:  C Bengala; F Bertolini; N Malavasi; C Boni; E Aitini; C Dealis; S Zironi; R Depenni; A Fontana; C Del Giovane; G Luppi; P Conte
Journal:  Br J Cancer       Date:  2009-11-24       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.